Global Alliance for Tb Drug Development

Pfizer Corporation

Hamish Scott Sutherland

Brian Desmond Palmer

William Alexander Denny

Zhenkun Ma

Andrew Mark Thompson

Adrian Blaser

Iveta Kmentova

Gordon William Rewcastle

Genliang Lu

Charles Z Ding

Julie Ann Spicer

Keith D Combrink

Jiancheng Wang

Jeremy Tyson Starr

Richard John Sciotti

Dianjun D Chen

Christopher Richardson

Minsoo Song

Andrew M Thompson

Diajun D Chen

The present invention relates to novel nitroimidazooxazines, to their preparation, and to their use as drugs for treatingand other microbial infections, either alone or in combination with other anti-infective treatments.

Nitroimidazooxazines and their uses in anti-tubercular therapy

The current invention provides a series of bicyclic nitroimidazole-substituted phenyl oxazolidinones in which a bicyclic nitroimidazole pharmacophore is covalently bonded to a phenyl oxazolidinone, their pharmaceutical compositions, and the method of use of the compositions for prevention and treatment of bacterial infections. The bicyclic nitroimidazole-substituted phenyl oxazolidinones possess surprising antibacterial activity against wild-type and resistant strains of pathogens, and are therefore useful for the prevention, control and treatment of a number of human and veterinary bacterial infections caused by these pathogens, such as

Bicyclic nitroimidazole-substituted phenyl oxazolidinones

Compounds of formula I and methods for their preparation are disclosed. Further disclosed are methods of making biologically active compounds of formula I as well as pharmaceutically acceptable compositions comprising compounds of formula I. Compounds of formula I as disclosed herein can be used in a variety of applications including use as antibacterial agents. 

Substituted Imidazo[1,2-a]pyridines as Antibacterial Agents

Growing community of inventors

Auckland, New Zealand

Hamish Scott Sutherland